Erbitux - Merck KGaA/Bristol-Myers Squibb

Cost: $137,953 per U.S. patient per year

Nowadays, Erbitux isn't just a cancer drug, which are often pricey in general. It's a targeted cancer drug. Back in 2009, the FDA allowed Merck ($MRK) to narrow Erbitux's indication for advanced colon cancer, changing the label to recommend the drug for treatment of EGFR-expressing tumors only in patients without a mutation in the KRAS gene.

The move may have narrowed Erbitux's patient pool, but the German pharma has said it thinks better efficacy data in a smaller group can help marketing teams stress the med's benefits. Analysts, though, don't appear sold; they expect the med's peak sales to hit $1.25 billion for Merck this year before slipping to $1.1 billion by 2018.

That's not such great news for Merck, for which Erbitux is a No. 2 seller. Its prescription drug business, Serono, is already struggling after not delivering a major new drug since 2013. Right now, though, the drug is on the rise, with sales expanding 5.9% in 2013.

For more:
Special Report: Top 10 best-selling cancer drugs of 2013 - Erbitux
Merck KGaA eyes KRAS-gene focus to boost Erbitux sales
Merck yanks European app for Erbitux in lung cancer
BMS, Lilly's targeted drug Erbitux gets new FDA nod

-- Carly Helfand (email | Twitter)

Erbitux - Merck KGaA/Bristol-Myers Squibb

Suggested Articles

Merck & Co. joined the pack in 2018 by hiring Jim Scholefield as its first chief digital officer. Now, less than two years in, he's moving on.

Teva is counting on Austedo for growth amid challenges elsewhere, and this week, the drug failed two trials in Tourette syndrome.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.